Solid Biosciences Inc.

SLDBNASDAQHealthcare● Active

$6.41

$-0.29(-4.33%)

Market Cap$499404382

P/E Ratio—

52W High$8.866

52W Low$3.675

Avg Volume1.3M

Open$6.84

Beta2.43

Free Cash Flow Financials Revenue

Solid Biosciences Inc. (SLDB) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

SLDB · free cash flow · updated Jun 8, 2026

Core FCF metrics

SLDB · FCF · TTM · margin & CAGR

Free cash flow was −$157.4M for FY2025 (fiscal year ending 2025-12-31), down 56.4% year-over-year

FY2025 Free Cash Flow−$157.4M▼ -56.4% YoY

Trailing 12M (TTM)−$172.9Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

SLDB · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$156.3M(1M)−$157.4M▼ 56.4%—

FY2024−$100.0M(1M)−$100.7M▼ 5.2%—

FY2023−$94.2M(2M)−$95.7M▲ +5.2%—

FY2022−$98.0M(3M)−$101.0M▼ 27.8%—

FY2021−$77.8M(1M)−$79.0M▼ 37.5%-580.4%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

SLDB · P/FCF · FCF yield · FCF per share

Solid Biosciences Inc. (SLDB) reported negative free cash flow of −$0.16B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

SLDB · cash flow statement · operating / investing / financing

For FY2025, Solid Biosciences Inc. generated −$156.3M in operating cash flow and spent 1M in capital expenditures, yielding −$157.4M in free cash flow.

Operating Activities

−$156.3M

Cash from core business operations

2025-12-31

Investing Activities

−$58.5M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$194.4M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$156.3M) − |CapEx| (1M) = FCF (−$157.4M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

SLDB vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Solid Biosciences Inc.YOU

SLDB

−$157.4M-56.4%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Solid Biosciences Inc. (SLDB) reported free cash flow of −$157.4M for FY2025 (fiscal year ending 2025-12-31), down 56.4% year-over-year.

Solid Biosciences Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 11 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

SLDB free cash flow · 8 questions

Solid Biosciences Inc. free cash flow was −$157.4M for FY2025, down 56.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$172.9M.

SLDB free cash flowSLDB FCFSLDB FCF 2025SLDB free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Solid Biosciences Inc. · Solid Biosciences Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026